Physician

Jane L Liesveld, MD

According to 2025 Medicare claims, Jane Liesveld, MD (NPI: 1851319610) practices hematopoietic cell transplantation and cellular therapy in the Rochester, NY market, with the plurality of this provider's patient population coming from Monroe, NY. This provider's primary affiliated billing organization is UNIVERSITY OF ROCHESTER (NPI: 1821152588; TIN: 160743209) and primary practice location at 14642-0001.

Liesveld's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 189 traditional Medicare patients, billed 663 HCPCS/CPT codes, and received $44,223 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 996 prescription claims across 138 beneficiaries totaling $5,236,648 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2023 DME data shows 32 claims. Open Payments data shows 14 records totaling $101,246. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,100,571 to $5,236,648. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	159	501	$33,800
2016	179	570	$38,213
2017	179	550	$36,483
2018	185	533	$35,074
2019	166	429	$28,183
2020	176	577	$40,996
2021	180	549	$49,439
2022	192	492	$40,918
2023	184	474	$38,622
2024	189	663	$44,223

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	119	1,162	$1,100,571
2016	145	1,253	$1,951,513
2017	119	1,399	$2,425,062
2018	116	1,320	$2,643,180
2019	126	1,250	$2,378,132
2020	133	1,257	$2,479,646
2021	140	1,382	$3,342,405
2022	158	1,499	$3,798,486
2023	161	1,498	$5,460,849
2024	138	996	$5,236,648

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$531
2016	N/R	22	$395
2017	N/R	94	$6,889
2018	N/R	81	$2,843
2019	N/R	53	$2,037
2020	N/R	28	$1,424
2021	N/R	58	$1,653
2022	N/R	47	$801
2023	N/R	32	$553
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	76	137	$99
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	30	151	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	97	124	$68
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	17	38	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	89	146	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	96	2,880	$1,277,651
Rezurock	Belumosudil Mesylate	32	960	$1,125,945
Lenalidomide	Lenalidomide	34	952	$508,176
Calquence	Acalabrutinib Maleate	27	1,050	$489,618
Inqovi	Decitabine/Cedazuridine	17	476	$138,528

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$3,367	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$97,879	STRONG MEMORIAL HOSPITAL
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jane L. Liesveld, MD?

Tedicare shows public-source Medicare data for Jane L. Liesveld, MD (NPI 1851319610), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jane L. Liesveld, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jane L. Liesveld, MD?

Jane L. Liesveld, MD is linked to UNIVERSITY OF ROCHESTER (billing NPI 1821152588) in the available physician profile data.

Does Jane L. Liesveld, MD have Open Payments data?

Jane L. Liesveld, MD has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.